What does the future hold for clinical studies in vasculitis?

Area of Science:

• Rheumatology and Immunology
• Clinical Trials and Therapeutics
• Translational Medicine

Background:

• Pre-1990: Reliance on single-center studies and pathology for understanding vasculitis, with cyclophosphamide (CyP) and glucocorticosteroids (GCS) as life-saving but toxic therapies.
• Limited cures for idiopathic large- and small-vessel vasculitis necessitated a focus on effective remission maintenance with minimal risk.

Observation:

• Early treatments like CyP/GCS were effective but carried severe adverse events.
• Safer alternatives like methotrexate (MTX) were identified for some vasculitis forms, but cures remained elusive.
• Large-scale collaborative networks and randomized controlled trials (RCTs) from 1990 onwards accelerated progress.

Findings:

• Modern treatments, including rituximab, are as effective as CyP for severe granulomatosis with polyangiitis (GPA, formerly Wegener's granulomatosis) and microscopic polyangiitis (MPA), without the long-term toxicities.
• Short courses of CyP remain valuable for life-saving interventions, with step-down therapy becoming standard.
• Research is exploring targeted therapies like interleukin-5 inhibition for Churg-Strauss syndrome (CSS) and anti-interferon-gamma for granulomatous vasculitides.

Implications:

• Future research aims to identify etiological factors for vasculitis, potentially leading to cures by understanding disease-driving antigens and patient vulnerabilities.
• Key unmet needs include increasing the number of trained vasculitis physicians and defining optimal risk-benefit strategies for maintenance therapy, treatment discontinuation, and laboratory monitoring.
• Investigating infection as a potential driver of autoimmunity is crucial, leveraging sophisticated pathogen discovery techniques.